Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells. Zoledronic acid may stop the
growth of tumor cells in bone. Giving chemotherapy with or without zoledronic acid before
surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be
removed. Giving these treatments after surgery may kill any tumor cells that remain after
surgery. It is not yet known whether giving combination chemotherapy together with zoledronic
acid is more effective than combination chemotherapy alone in treating osteosarcoma.
PURPOSE: This randomized phase III trial is studying combination chemotherapy and zoledronic
acid to see how well they work compared with combination chemotherapy alone in treating
patients with osteosarcoma.
Phase:
Phase 3
Details
Lead Sponsor:
UNICANCER
Collaborators:
Chugai Pharmaceutical Ligue contre le cancer, France National Cancer Institute, France Novartis SFCE